Skip to main content

Table 2 Crude and adjusted odds ratios† comparing 40 mg (n = 2445) and 30 mg (n = 1465) dose of stavudine on outcomes

From: Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa

Outcome Exposure

N (%)

Crude OR†

(95% CI)

Adjusted OR ††

(95% CI)

Six months

    

   Virologic failure

30 mg

44 (4.2%)

1

1

 

40 mg

133 (7.6%)

1.86 (1.31-2.64)

1.69 (0.81-3.52)

   Stavudine discontinuation

30 mg

60 (4.1%)

1

1

 

40 mg

135 (5.5%)

1.37 (1.00-1.87)

0.87 (0.45-1.71)

   Peripheral neuropathy

30 mg

31 (2.1%)

1

1

 

40 mg

220 (9.0%)

4.57 (3.12-6.70)

3.17 (1.71-5.90)

Twelve months

    

   Virologic failure

30 mg

58 (5.0%)

1

1

 

40 mg

208 (10.6%)

2.27 (1.68-3.06)

1.62 (0.88-2.97)

   Stavudine discontinuation

30 mg

158 (10.8%)

1

1

 

40 mg

413 (16.9%)

1.68 (1.38-2.05)

1.71 (1.13-2.57)

   Peripheral neuropathy

30 mg

41 (2.8%)

1

1

 

40 mg

357 (14.6%)

5.94 (4.27-8.26)

3.12 (1.86-5.25)

   Lipoatrophy

30 mg

4 (0.3%)

1

1

 

40 mg

81 (3.3%)

12.5 (4.6-34.2)

11.8 (3.2-43.8)

   Hyperlactemia/lactic acidosis

30 mg

15 (1.0%)

1

1

 

40 mg

179 (7.3%)

7.64 (4.49-12.99)

8.37 (3.83-18.29)

  1. †OR = Odds ratios estimated using logistic regression models
  2. ††Estimates adjusted for baseline weight, height, age, gender, ethnicity, employment status, haemoglobin, CD4 count, WHO stage, tuberculosis status, reported baseline peripheral neuropathy, calendar date, and whether clinical care was free at baseline